Avidity Biosciences prices upsized offering of 15M shares at $40, raising ~$564M net

Avidity Biosciences, Inc.

Priced upsized public offering of 15M shares at $40/share; underwriters have 30-day option for 2.25M additional shares.
Net proceeds expected ~$564M (or $648.8M if option fully exercised); closing set for September 15, 2025.
Proceeds to fund three late-stage clinical programs, commercial inventory build, infrastructure, and AOC platform R&D.
Joint bookrunners: Leerink Partners, J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.